Drug Profile


Alternative Names: Anapsos

Latest Information Update: 10 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator A.S.A.C. Pharma
  • Class Antidementias; Glycosides; Neuroprotectants; Nootropics; Phytotherapies; Skin disorder therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease; Multiple sclerosis

Most Recent Events

  • 08 May 2003 Phase-I clinical trials in Multiple sclerosis in Spain (unspecified route)
  • 26 Feb 2001 Investigation in Multiple sclerosis in Spain (Unknown route)
  • 26 Feb 2001 Phase-II clinical trials for Alzheimer's disease in Spain (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top